Submitted:
15 June 2024
Posted:
17 June 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
- Unvaccinated,
- First dose less than 21 days before (1D<21d),
- First dose at least 21 days before (1D≥21d),
- Second dose less than 21 days before (2D<21d),
- Second dose at least 21 days before (2D≥21d),
- Third dose or booster less than 21 days before (3D<21d),
- Third dose or booster at least 21 days before (3D≥21d).
2.1. Statistical Analysis
3. Results
3.1. About ONS Dataset
3.2. Population Distributions
3.3. Rate Ratios (RR)
- for the 60-69 years age group, the risk of death significantly exceeds that of the unvaccinated in the months of November and December 2022 and remains in the following months not significantly different from that of the unvaccinated;
- for the 70-79 years age group the RR exceeds the reference value in June 2022 and always remains significantly higher, apart from the months of September 2022 and May 2023 where the values are not significative;
- for the 80-89 years age group the RR exceeds the reference value in April 2022, reaches the maximum value (RR = 2.29, CI95 = 2.04-2.58) and then stabilizes on values always significantly higher than 1;
- for vaccinated people aged 90 years and over, the reference value is exceeded in April 2022 (RR = 1.13, CI95 = 1.02-1.26), then remaining at values always significantly higher than 1, with a maximum of 1.85 in November 2022.
3.4. Standardized Mortality Ratios







4. Discussion
- (a)
- compared with unvaccinated, vaccinated with one or two doses show, in the period April 2021-May 2023, a substantially higher risk of all-causes and non-COVID-19 deaths. Indeed, for both causes people vaccinated with one dose show a RR significatively higher than 1 thorough almost the whole period and in any of the age groups, except the 18-39 years, in which it is significatively higher in half the period. In people who received the second dose, from 60 to 90+ years of age the risk of all-causes and non-COVID-19 death is significatively higher than in unvaccinated people thorough about the final two thirds of the period. It should be noted that from 50 to 90+ years of age the RRs of all-causes and non-COVID-19 death have implausibly low initial values.
- (b)
- Also vaccinated with three doses have incredibly low initial values of RR both for all-causes and for non-COVID-19 deaths. Their RRs, for people aged 60-69 and older progressively grow up to reach and exceed the reference value from 60 years of age, and from 70 years and over the RRs remain significantly greater than 1.
- (c)
- A linear growth trend is revealed by regression analysis of Standardized Mortality Ratios of people vaccinated with any dose compared to the unvaccinated across all age groups, for both all-cause and non-COVID-19 deaths. The regression lines, both for all-cause deaths and for non-COVID-19 ones, start from very low values for all the age groups. For the age groups 18-39, 80-89 and 90+ years both regression lines intersect the reference line of unvaccinated during the study period. The same occurs for the age 50-59, limited to non-COVID-19 deaths, For the other age groups, we have predicted the month of the intersection (see Table 1).
4.1. Underestimation of the Unvaccinated Population
4.2. The Healthy-Vaccinee Bias
4.3. The Harvesting Effect
4.4. Loss of Protective Vaccine Effectiveness and Lower Lethality of New Variants
4.5. Unintended Effects of COVID-19 Vaccines on the Increasing Deaths
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hussain, Z. England and Wales have seen rise in excess deaths in 2022. BMJ 2022, 378, o2283. [Google Scholar] [CrossRef] [PubMed]
- Deaths registered weekly in England and Wales, provisional: week ending 26 May 2023. Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/weekending26may2023 (accessed on 1 May 2024).
- Schöley, J.; Aburto, J.M.; Kashnitsky, I.; Kniffka, M.S.; Zhang, L.; Jaadla, H.; Dowd, J.B.; Kashyap, R. Life expectancy changes since COVID-19. Nat. Hum. Behav. 2022, 6, 1649–1659. [Google Scholar] [CrossRef] [PubMed]
- Deaths by vaccination status, England. Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingcovid19byvaccinationstatusengland/deathsoccurringbetween1april2021and31may2023 (accessed on 1 May 2024).
- Our world in data - Share of people vaccinated against COVID-19, Apr 25, 2021. Available online: https://ourworldindata.org/covid-vaccinations?country=GBR (accessed on 1 May 2024).
- Donzelli, A.; Malatesta, G.; Di Palmo, G.; Cosentino, M.; Alessandria, M. All-Cause Mortality According to COVID-19 Vaccination Status: an analysis of the UK Office for National Statistics Public Data. Preprints 2023, 2023020414. [Google Scholar] [CrossRef]
- Soliani, L. Statistica Applicata, Uni. Nova: Parma (PR), Italy, 2008.
- Norman, G.; Streiner, D. Biostatistica, 2nd ed.; Casa Editrice Ambrosiana: Rozzano (MI), 2015. [Google Scholar]
- Altman, D.G.; Bland, J.M. How to obtain the confidence interval from a P value. BMJ 2011, 343, d2090. [Google Scholar] [CrossRef] [PubMed]
- Naing, NN. Easy way to learn standardization: direct and indirect methods. Malays J Med Sci. 2000, 7, 10–15. [Google Scholar] [PubMed] [PubMed Central]
- Acuti Martellucci, C.; Flacco, M.E.; Soldato, G.; Di Martino, G.; Carota, R.; Caponetti, A.; Manzoli, L. Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. Vaccines 2022, 10, 662. [Google Scholar] [CrossRef] [PubMed]
- Rosso, A.; Flacco, M.E.; Soldato, G.; Di Martino, G.; Acuti Martellucci, C.; Carota, R.; De Benedictis, M.; Di Marco, G.; DiLuzio, R.; Fiore, M.; et al. COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follo Up. Vaccines 2023, 11, 1325. [Google Scholar] [CrossRef] [PubMed]
- Berrino F, Donzelli A, Bellavite P, Malatesta G. COVID-19 vaccination and all-cause and non-COVID-19 mortality. A revaluation of a study carried out in an Italian Province. Epidemiol Prev. 2023, 47, 374–378. [Google Scholar] [CrossRef] [PubMed]
- Pinsky, P.F.; Miller, A.; Kramer, B.S.; Church, T.; Reding, D.; Prorok, P.; Gelmann, E.; Schoen, R.E.; Buys, S.; Hayes, R.B.; Berg, C.D. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am. J. Epidemiol. 2007, 165, 874–881. [Google Scholar] [CrossRef]
- Dormuth, C.R.; Patrick, A.R.; Shrank, W.H. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009, 119, 2051–2057. [Google Scholar] [CrossRef]
- Vestbo, J.; Anderson, J.A.; Calverley, P.M.; Celli, B.; Ferguson, G.T.; Jenkins, C.; Knobil, K.; Willits, L.R.; Yates, J.C.; Jones, P.W. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009, 64, 939–943. [Google Scholar] [CrossRef]
- Ladova, K.; Vlcek, J.; Vytrisalova, M.; Maly, J. Healthy adherer effect - the pitfall in the interpretation of the effect of medication adherence on health outcomes. J. Eval. Clin. Pract. 2014, 20, 111–116. [Google Scholar] [CrossRef] [PubMed]
- Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N. Engl. J. Med. 1980, 303, 1038–1041. [Google Scholar] [CrossRef] [PubMed]
- Simpson, S.H.; Eurich, D.T.; Majumdar, S.R.; Padwal, R.S.; Tsuyuki, R.T.; Varney, J.; Johnson, J.A. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006, 333, 15. [Google Scholar] [CrossRef] [PubMed]
- Jackson, L.A.; Jackson, M.L.; Nelson, J.C.; Neuzil, K.M.; Weiss, N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int. J. Epidemiol. 2006, 35, 337–344. [Google Scholar] [CrossRef] [PubMed]
- Horwitz, R.I.; Viscoli, C.M.; Berkman, L.; Donaldson, R.M.; Horwitz, S.M.; Murray, C.J.; Ransohoff, D.F.; Sindelar, J. Treatment adherence and risk of death after a myocardial infarction. The Lancet 1990, 336, 542–545. [Google Scholar] [CrossRef] [PubMed]
- Furst T, Straka R, Janosek J. Healthy vaccinee effect: a bias not to be forgotten in observational studies on COVID-19 vaccine effectiveness. Pol Arch Intern Med. 2024, 134, 16634. [Google Scholar] [CrossRef] [PubMed]
- 23. Fürst T, Bazalová A, Fryčák T, Janošek J. Does the healthy vaccinee bias rule them all? Association of COVID-19 vaccination status and all-cause mortality from an analysis of data from 2.2 million individual health records. Int J Infect Dis. 2024, 142, 106976. [Google Scholar] [CrossRef] [PubMed]
- McCarthy NL, Weintraub E, Vellozzi C, Duffy J, Gee J, Donahue JG, Jackson ML, Lee GM, Glanz J, Baxter R, Lugg MM, Naleway A, Omer SB, Nakasato C, Vazquez-Benitez G, DeStefano F. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013, 45, 91–97. [Google Scholar] [CrossRef]
- Redelmeier, D.A.; Wang, J.; Thiruchelvam, D. COVID Vaccine Hesitancy and Risk of a Traffic Crash. Am. J. Med. 2023, 136, 153–162. [Google Scholar] [CrossRef]
- Remschmidt, C.; Wichmann, O.; Harder, T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: A systematic review. BMC Infect. Dis. 2015, 15, 429. [Google Scholar] [CrossRef]
- Eythorsson E, Runolfsdottir HL, Ingvarsson RF, Sigurdsson MI, Palsson R. Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland. JAMA Netw Open. 2022, 5, e2225320. [Google Scholar] [CrossRef]
- Tseng, H.F. , Ackerson, B.K., Bruxvoort, K.J. et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun 2023, 14, 189. [Google Scholar] [CrossRef] [PubMed]
- Chemaitelly H, Ayoub HH, Tang P, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect Dis. 2023, 23, 816–827. [Google Scholar] [CrossRef] [PubMed]
- Tamandjou C, Auvigne V, Schaeffer J, et al. Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. Vaccine. 2023, 41, 2754–2760. [Google Scholar] [CrossRef]
- Shrestha NK, Burke PC, Nowacki AS, et al. Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine. Open Forum Infect Dis. 2023, 10, ofad209. [Google Scholar] [CrossRef]
- Qassim SH, Chemaitelly H, Ayoub HH, et al. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study. EClinicalMedicine. 2023, 62, 102102. [Google Scholar] [CrossRef] [PubMed]
- Chalupka A, Richter L, Chakeri A, El-Khatib Z, Theiler-Schwetz V, Trummer C, Krause R, Willeit P, Benka B, Ioannidis JPA, Pilz S. Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria. Eur J Clin Invest. 2024, 54, e14136. [Google Scholar] [CrossRef]
- Shrestha NK, Burke PC, Nowacki AS, Gordon SM. Risk of Coronavirus Disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria. PLoS One. 2023, 18, e0293449. [Google Scholar] [CrossRef]
- Wang H, Xu Q, Zhao C, et al. An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy. J Immunother Cancer. 2020, 8, e000661. [Google Scholar] [CrossRef]
- Uversky VN, Redwan EM, Makis W, Rubio-Casillas A. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines (Basel). 2023, 11, 991. [Google Scholar] [CrossRef] [PubMed]
| Age group | Variables | R2 | p-value | intersection |
|---|---|---|---|---|
| 18-39 | All-causes death | 0,601 | <0.0001 | January, 2023 |
| Non-COVID-19 deaths | 0,500 | 0,0005 | January, 2023 | |
| 40-49 | All-causes death | 0,712 | <0.0001 | September, 2023 |
| Non-COVID-19 deaths | 0,463 | 0,0003 | April, 2023 | |
| 50-59 | All-causes death | 0,734 | <0.0001 | July, 2024 |
| Non-COVID-19 deaths | 0,609 | <0.0001 | January, 2025 | |
| 60-69 | All-causes death | 0,847 | <0.0001 | February, 2024 |
| Non-COVID-19 deaths | 0,745 | <0.0001 | May, 2024 | |
| 70-79 | All-causes death | 0,860 | <0.0001 | January, 2024 |
| Non-COVID-19 deaths | 0,764 | <0.0001 | May, 2024 | |
| 80-89 | All-causes death | 0,784 | <0.0001 | April, 2023 |
| Non-COVID-19 deaths | 0,706 | <0.0001 | January, 2023 | |
| 90+ | All-causes death | 0,695 | <0.0001 | September, 2022 |
| Non-COVID-19 deaths | 0,705 | <0.0001 | May, 2022 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).